Company Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
17.15 USD -1.27% Intraday chart for Entrada Therapeutics, Inc. +21.37% +13.65%

Business Summary

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Number of employees: 160

Sales per Business

USD in Million2022Weight2023Weight Delta
Endosomal Escape Vehicle Therapeutics
100.0 %
0 nan % 129 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 129 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 48 17-07-31
Director of Finance/CFO 45 20-10-31
President 54 19-11-03
Chief Tech/Sci/R&D Officer 62 17-08-31
Corporate Officer/Principal - 21-05-31
General Counsel - 20-03-31
Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 20-11-30
Director/Board Member 64 21-05-03
Director/Board Member 57 23-08-31
Chief Executive Officer 48 17-07-31
Chairman 42 16-09-30
Director/Board Member 60 23-04-03

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,992,120 31,376,734 ( 84.82 %) 21,064 ( 0.0569 %) 84.82 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
13.11 %
4,865,819 13.11 % 69 M $
Baker Bros. Advisors LP
13.11 %
4,865,819 13.11 % 69 M $
MPM BioImpact, Inc
11.92 %
4,425,784 11.92 % 63 M $
5AM Venture Management LLC
11.87 %
4,408,379 11.87 % 63 M $
T. Rowe Price International Ltd.
7.416 %
2,753,357 7.416 % 39 M $
2,744,120 7.391 % 39 M $
1,739,768 4.686 % 25 M $
BlackRock Advisors LLC
3.776 %
1,401,779 3.776 % 20 M $
Redmile Group LLC
3.458 %
1,283,735 3.458 % 18 M $
Vanguard Fiduciary Trust Co.
2.906 %
1,078,908 2.906 % 15 M $

Company contact information

Entrada Therapeutics, Inc.

One Design Center Place

02210, Boston

+

http://www.entradatx.com
address Entrada Therapeutics, Inc.(TRDA)
  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. Company Entrada Therapeutics, Inc.